Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation

Targeted therapy is the optimal treatment of patients with advanced EGFR-positive NSCLC. The first- and second-generation EGFR tyrosine kinase inhibitors provide a durable antitumor response in most patients during the year. Due to appearance of T790M secondary mutation of resistance at progression...

Full description

Saved in:
Bibliographic Details
Published inMedical Council no. 19; pp. 130 - 135
Main Authors Nelyubina, L. A., Reutova, E. V., Laktionov, K. K., Yudin, D. I., Marinov, D. T., Kozak, E. N., Mochalnikova, V. V.
Format Journal Article
LanguageEnglish
Russian
Published Remedium Group LLC 11.11.2018
Subjects
activating mutations
egfr
egfr tyrosine kinase inhibitors
non-small cell lung cancer
rebiopsy
resistance
small cell cancer
Online AccessGet full text

Cover

More Information
Summary:Targeted therapy is the optimal treatment of patients with advanced EGFR-positive NSCLC. The first- and second-generation EGFR tyrosine kinase inhibitors provide a durable antitumor response in most patients during the year. Due to appearance of T790M secondary mutation of resistance at progression of the disease, the administration of osimertinib leads to full control of the tumour for another 10 months. However, this is not the only mechanism of acquired drug resistance. A repeated biopsy of the tumour followed by histological and molecular genetic research makes it possible to clarify the cause of resistance and personalize the further disease management.
ISSN:2079-701X
2658-5790
DOI:10.21518/2079-701X-2018-19-130-135